Clinical Trials on Noncontiguous Stage II Marginal Zone Lymphoma

Total 533 results

National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
International Extranodal Lymphoma Study Group (IELSG)

Completed

Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)

Marginal Zone B-cell Lymphoma

Italy, Switzerland, Austria
Reid Merryman, MD
Genentech, Inc.

Recruiting

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-hodgkin Lymphoma

United States
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Merck Sharp & Dohme LLC

Terminated

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) (VEIL)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

Australia
Gilead Sciences

Terminated

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-hodgkin's Lymphoma | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
National Cancer Institute (NCI)

Completed

MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
IGM Biosciences, Inc.
ADC Therapeutics S.A.

Active, not recruiting

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCL

United States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
BeiGene

Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma

China
University Hospital Muenster
International Lymphoma Radiation Oncology Group (ILROG)

Recruiting

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

Follicular Lymphoma (Gastric or Duodenal) | Marginal Zone Lymphoma (Gastric or Duodenal)

Germany
National Cancer Institute (NCI)

Terminated

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Amir Mortazavi
National Cancer Institute (NCI); Arno Therapeutics

Completed

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse... and other conditions

United States
Ohio State University Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic... and other conditions

United States
Royal Marsden NHS Foundation Trust

Unknown

Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 (BMPB)

Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
BeiGene, Ltd.

Recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory... and other conditions

United States
Heidelberg University
Roche Pharma AG

Active, not recruiting

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (GAZAI)

Stage II Grade 1 Follicular Lymphoma | Stage II Grade 2 Follicular Lymphoma | Stage I Follicular Lymphoma Grade 1 | Stage II Follicular Lymphoma Grade 2

Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Extranodal Marginal Zone Lymphoma of Mucosa-Associated... and other conditions

United States
Korea Cancer Center Hospital

Unknown

131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Relapsed or Refractory Marginal Zone B-cell Lymphoma

Korea, Republic of
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

Marginal Zone Lymphoma of Ocular Adnexal

Italy
Acepodia Biotech, Inc.

Recruiting

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | DLBCL | Primary Mediastinal Large B Cell Lymphoma

United States, Taiwan
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
University of Miami
AstraZeneca

Terminated

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Small Lymphocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Cutaneous B-cell Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Adult Grade III Lymphomatoid... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom Macroglobulinemia

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma | Chronic Lymphocytic Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann... and other conditions

United States
National Cancer Institute (NCI)

Completed

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
HaEmek Medical Center, Israel

Completed

Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease (B-RAF V600E)

Splenic Marginal Zone Lymphoma | Hairy Cell Leukemia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
Abramson Cancer Center at Penn Medicine

Completed

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Marginal Zone B-Cell Lymphoma | MALT Lymphoma | Lymphoma of Mucosa-Associated Lymphoid Tissue

United States
Hospices Civils de Lyon

Active, not recruiting

BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. (BCL6-RINHL)

Follicular Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

France
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent... and other conditions

United States
Polish Lymphoma Research Group

Completed

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (PLRG4)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

Poland
National Cancer Centre, Singapore
Samsung Medical Center; Singapore General Hospital

Terminated

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Lymphoma, B-Cell, Marginal Zone

Singapore
Yazeed Sawalha

Recruiting

Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

United States
M.D. Anderson Cancer Center

Recruiting

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

Lymphoma

United States
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Lymphoma

Belgium, United States, France, Israel, Italy, United Kingdom, Germany, Spain, Poland, Australia, Argentina, Denmark
Andres J. M. Ferreri

Completed

Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma (HD-K)

Lymphoma

Italy
Oncternal Therapeutics, Inc
University of California, San Diego; Pharmacyclics LLC.; California Institute...

Active, not recruiting

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States

Clinical Trials on Noncontiguous Stage II Marginal Zone Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations